Article | June 6, 2022

Digital Biomarkers And Endpoints: Why They Matter In A DCT Setting

Source: Medable
GettyImages-1327073750 ps

Various data points, including digital biomarkers, are critical in helping researchers assess the efficacy and safety of therapeutics in decentralized clinical trials (DCTs).

With the increased availability and reliability of personal medical devices, consumers and researchers alike have access to a wider range of digital biomarkers than ever before. Devices and apps count steps, track heart rate, assess sleep quantity and quality, and continuously track blood glucose and blood pressure levels, among other biomarkers.

The global market for wearable medical devices is estimated to be $12.1 billion this year, and approximately 30% of smartphone users in the U.S. use at least one health app.

For many interventions under study, the data of daily living gathered via these devices may be as important as the data gathered during routine laboratory check-ins with clinical trial participants. So, it follows that digital biomarkers stand to have a profound impact on — and even enable — the digital transformation of the healthcare industry and DCTs.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader